SAN DIEGO, Aug. 3, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the second quarter 2015 on Monday, August 10, 2015 at 4:30 p.m. ET/1:30 p.m. PT. Dr. Helen Torley, president and chief executive officer, will lead the call. On the same date post-market, Halozyme will release financial results for the second quarter 2015.
The call will be webcast live through the "Investors" section of Halozyme's corporate website and a recording will be made available following the call. To access the webcast and additional documents related to the call, please log on to halozyme.com approximately fifteen minutes prior to the call to register, download and install any necessary audio software. The live call may be accessed by calling (866) 710-0179 (domestic callers) or (334) 323-7224 (international callers) using passcode 769890. A telephone replay will be available after the call by dialing (877) 919-4059 (domestic callers) or (334) 323-0140 (international callers) using replay ID number 53958140.
About Halozyme Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. Halozyme's lead proprietary program, investigational drug PEGPH20, applies a unique approach to targeting solid tumors, allowing increased access of co-administered cancer drug therapies to the tumor. PEGPH20 is currently in development for metastatic pancreatic cancer, non-small cell lung cancer, metastatic breast cancer and has potential across additional cancers in combination with different types of cancer therapies. In addition to its proprietary product portfolio, Halozyme has established value-driving partnerships with leading pharmaceutical companies including Roche, Baxalta, Pfizer, Janssen and AbbVie for its drug delivery platform, ENHANZE™, which enables biologics and small molecule compounds that are currently administered intravenously to be delivered subcutaneously. Halozyme is also pursuing clinical collaborations with biopharmaceutical companies including Eisai, to evaluate the pan-tumor potential of PEGPH20. Halozyme is headquartered in San Diego. For more information visit halozyme.com.
Contacts: Schond Greenway Halozyme Therapeutics 858-704-8352 firstname.lastname@example.org
Jim Mazzola Halozyme Therapeutics 858-704-8122 email@example.com
SOURCE Halozyme Therapeutics, Inc.